Literature DB >> 16239766

Levetiracetam in porphyric status epilepticus: a case report.

Megdad M Zaatreh1.   

Abstract

Status epilepticus in patients with acute intermittent porphyria (AIP) are difficult to treat. In this report the author describes a patient with AIP and status epilepticus who was successfully treated with a combination of intravenous magnesium and levetiracetam. This case and the limited experience reported in the literature show that it is probably safe to administer levetiracetam in patients with AIP; however, its role in the treatment of status epilepticus deserves further evaluation.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16239766     DOI： 10.1097/01.wnf.0000185828.80561.ad

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN： 0362-5664            Impact factor:   1.592


  11 in total

1.  [A 25-year-old patient with colonic pseudo-obstruction, hyponatremia, hypertension, and diffuse pain].

Authors:  Philipp Lutz; Daniel Maring; Henriette J Tschampa; Tilman Sauerbruch
Journal:  Med Klin (Munich)       Date:  2010-04

2.  New treatment options in status epilepticus: a critical review on intravenous levetiracetam.

Authors:  Eugen Trinka; Judith Dobesberger
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

3.  Treatment of seizures in the neurologic intensive care unit.

Authors:  Panayiotis N Varelas; Marek Mirski
Journal:  Curr Treat Options Neurol       Date:  2007-03       Impact factor: 3.598

4.  Levetiracetam in idiopathic generalised epilepsy and porphyria cutanea tarda.

Authors:  Leonilda Bilo; Roberta Meo; Maria Fulvia de Leva
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

Review 5.  Generalised convulsive status epilepticus: an overview.

Authors:  R Nandhagopal
Journal:  Postgrad Med J       Date:  2006-11       Impact factor: 2.401

6.  Treatment of Refractory Convulsive Status Epilepticus: A Comprehensive Review by the American Epilepsy Society Treatments Committee.

Authors:  David G Vossler; Jacquelyn L Bainbridge; Jane G Boggs; Edward J Novotny; Tobias Loddenkemper; Edward Faught; Marta Amengual-Gual; Sarah N Fischer; David S Gloss; Donald M Olson; Alan R Towne; Dean Naritoku; Timothy E Welty
Journal:  Epilepsy Curr       Date:  2020-08-21       Impact factor: 7.500

Review 7.  Therapeutic Options for Patients with Refractory Status Epilepticus in Palliative Settings or with a Limitation of Life-Sustaining Therapies: A Systematic Review.

Authors:  Laurent M Willems; Sebastian Bauer; Kolja Jahnke; Martin Voss; Felix Rosenow; Adam Strzelczyk
Journal:  CNS Drugs       Date:  2020-08       Impact factor: 5.749

8.  Levetiracetam in the treatment of epilepsy.

Authors:  Bassel Abou-Khalil
Journal:  Neuropsychiatr Dis Treat       Date:  2008-06       Impact factor: 2.570

9.  Acute porphyria presenting as epilepsia partialis continua.

Authors:  Thi Phuoc Yen Tran; Karine Leduc; Martin Savard; Nicolas Dupré; Donald Rivest; Dang Khoa Nguyen
Journal:  Case Rep Neurol       Date:  2013-06-29

10.  Clinical, Biochemical Characteristics and Hospital Outcome of Acute Intermittent Porphyria Patients: A Descriptive Study from North India.

Authors:  Susheel Kumar; Ashish Bhalla; Navneet Sharma; Deba Prasad Dhibar; Savita Kumari; Subhash Varma
Journal:  Ann Indian Acad Neurol       Date:  2017 Jul-Sep       Impact factor: 1.383
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.